MedImmune
MedImmune, Inc.
MedImmune was a subsidiary of AstraZeneca. In February 2019 the MedImmune name and branding was discontinued in favor of AstraZeneca.
Website: https://www.astrazeneca.com/Careers: careers.astrazeneca.com
Latest news
- FluMist Approved for Self-Administration in the US
20 September 2024 - FDA Approves FluMist Quadrivalent Vaccine to Prevent Seasonal Influenza
1 March 2012 - Medimmune Receives Complete Response Letter On Motavizumab
7 September 2010 - FDA Advisory Committee Reviews MedImmune's Motavizumab
3 June 2010 - MedImmune Receives FDA Complete Response Letter on Motavizumab
1 December 2008 - MedImmune Submits Biologics License Application to FDA for
Motavizumab
4 February 2008 - FDA Approves Expanded Label for FluMist to Include Children Two to Five Years of Age
19 September 2007 - FDA Advisory Committee Recommends Expanded Use of FluMist
16 May 2007 - FDA Approves MedImmune's Refrigerated Formulation of FluMist
9 January 2007 - FDA Approves FluMist for Prevention of Influenza
17 June 2003
Drugs Associated with MedImmune, Inc.
MedImmune, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
FluMist Quadrivalent
Generic name: influenza virus vaccine, live Drug class: viral vaccines |
1 review | 1.0 / 10 |
|
Lumoxiti
Generic name: moxetumomab pasudotox Drug class: miscellaneous antineoplastics |
||
|
Synagis
Generic name: palivizumab Drug class: antiviral monoclonal antibodies |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
Discontinued Drugs
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Neutrexin
Generic name: trimetrexate Drug class: miscellaneous antibiotics |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||